Accéder au contenu
Merck

The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2004-06-03)
Xiao-Dong Chen, Larry W Fisher, Pamela Gehron Robey, Marian F Young
RÉSUMÉ

Biglycan (bgn) is a small leucine-rich proteoglycan enriched in extracellular matrices of skeletal tissues. Bgn-deficient mice develop age-related osteopenia with a phenotype that resembles osteoporosis and premature arthritis. In the present study, we have examined the differentiation of bgn-deficient osteoblasts from neonatal murine calvariae and found that the absence of bgn caused less BMP-4 binding, which reduced the sensitivity of osteoblasts to BMP-4 stimulation. The loss of sensitivity resulted in a reduction of Cbfa1 expression, which ultimately led to a defect in the differentiation of osteoblasts. However, the response of bgn-deficient osteoblasts to BMP-4 was completely rescued by reintroduction of biglycan by viral transfection. We propose that biglycan modulates BMP-4-induced signaling to control osteoblast differentiation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Biglycan from bovine articular cartilage, (essentially salt-free (from 0.2 μm filtered solution))